말기 신부전(ESRD) 치료제 시장 보고서(2026년)

End stage renal disease (ESRD) drugs are medications used to manage a condition in which a person's kidneys permanently lose function, necessitating a kidney transplant or ongoing long-term dialysis to sustain life. These drugs play a vital role in treating the disease and preventing secondary complications in patients with chronic kidney disease (CKD).

The primary types of end stage renal disease (ESRD) drugs include calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics are used to lower parathyroid hormone (PTH) levels in patients with stage 5D kidney disease, based on serum calcium and phosphorus concentrations. Key indications include ESRD-induced hyperparathyroidism, ESRD-induced hyperphosphatemia, and ESRD-induced hyperkalemia. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and are used across hospitals, homecare settings, specialty clinics, and other end users.

Tariffs have influenced the ESRD drug market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials, leading to higher production costs and supply chain disruptions. The impact is most pronounced in segments like vitamin D analogs and calcimimetics, especially in regions reliant on imports such as Asia-Pacific and Africa. Hospitals and specialty clinics face increased procurement costs, whereas domestic manufacturers may benefit from reduced competition, prompting investment in local production and innovation to optimize cost-effective therapies.

The end stage renal disease (esrd) drug market research report is one of a series of new reports from The Business Research Company that provides end stage renal disease (esrd) drug market statistics, including end stage renal disease (esrd) drug industry global market size, regional shares, competitors with a end stage renal disease (esrd) drug market share, detailed end stage renal disease (esrd) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (esrd) drug industry. This end stage renal disease (esrd) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $148.55 billion in 2025 to $171.12 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to growing prevalence of ckd, increasing awareness of esrd, rise in dialysis centers, advancements in renal therapeutics, government healthcare initiatives.

The end stage renal disease (esrd) drug market size is expected to see rapid growth in the next few years. It will grow to $304.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to development of precision medicine, expansion of homecare dialysis, integration of ai in patient monitoring, rising investments in esrd r&d, growing adoption of combination therapies. Major trends in the forecast period include personalized esrd drug therapy, home-based dialysis solutions, telemedicine integration in ckd management, advanced drug formulations for secondary complications, increasing adoption of combination therapies.

The increasing prevalence of obesity and diabetes is expected to drive the growth of the end-stage renal disease (ESRD) drug market in the coming years. Obesity is defined as excessive or abnormal fat accumulation that presents a health risk, while diabetes is a long-term condition that occurs when the pancreas produces insufficient insulin or when the body cannot effectively use the insulin it produces. In individuals with renal disease, effective management of fluid and electrolyte balance, blood pressure, and waste removal through dialysis can enhance overall health and well-being, potentially contributing to weight loss and better blood glucose control. For example, in 2023, the World Obesity Federation, a non-profit membership organization, projected that by 2035 the economic burden of overweight and obesity would reach US$4.32 trillion annually, representing nearly 3% of the global economy. Additionally, in June 2024, according to the National Health Service, a UK-based government body, 3,615,330 people registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, reflecting an 18% increase from 3,065,825 cases in 2022. Therefore, the rising incidence of obesity and diabetes is fueling the growth of the end-stage renal disease (ESRD) drug market.

Major companies operating in the end-stage renal disease (ESRD) drug market are emphasizing product approvals, such as Jardiance, to boost their market revenues. Empagliflozin is a medication designed to support individuals with type 2 diabetes and to reduce the risk of cardiovascular complications in patients with type 2 diabetes who also have heart failure or cardiovascular disease. For example, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, received FDA approval for Jardiance. Jardiance has been approved for multiple indications, including reducing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression, as well as decreasing the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults with heart failure. Jardiance is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor and is contraindicated for patients with type 1 diabetes and those with an eGFR below 20 ml/min/1.73 m2.

In May 2024, Vertex Pharmaceuticals, a U.S.-based biotechnology company focused on developing therapies for genetic disorders and immunology, acquired Alpine Immune Sciences for an undisclosed sum. Through this acquisition, Vertex sought to broaden its renal disease portfolio by obtaining povetacicept, Alpine's lead candidate targeting IgA nephropathy (IgAN), a chronic autoimmune kidney condition that can progress to end-stage renal disease, while also integrating Alpine's protein engineering and immunotherapy expertise. Alpine Immune Sciences is a U.S.-based clinical-stage biotechnology company specializing in engineered immunotherapies, with its dual BAFF/APRIL antagonist povetacicept expected to advance into Phase 3 development for IgAN.

Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the end stage renal disease (esrd) drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

End Stage Renal Disease (ESRD) Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses end stage renal disease (esrd) drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for end stage renal disease (esrd) drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The end stage renal disease (esrd) drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders; Other Products
• 2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism; End Stage Renal Disease (ESRD) Induced Hyperphosphatemia; End Stage Renal Disease (ESRD) Induced Hyperkaliemia
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Calcimimetics: Cinacalcet; Etelcalcetide
• 2) By Vitamin D: Calcitriol; Doxercalciferol; Paricalcitol
• 3) By Sterols: Ergocalciferol; Cholecalciferol
• 4) By Potassium Binders: Sodium Polystyrene Sulfonate; Patiromer; Sodium Zirconium Cyclosilicate
• 5) By Calcium-Based Phosphate Binders: Calcium Acetate; Calcium Carbonate
• 6) By Other Products: Iron Supplements; Erythropoiesis-Stimulating Agents
• Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Sanofi SA; Astellas Pharma Inc.; Novartis AG; Fresenius SE & Co. KGaA; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd.; Kissei Pharmaceutical Co. Ltd.; Baxter International Inc.; AbbVie Inc.; Amgen Inc.; Akebia Drugs Inc.; Bayer AG; Bristol-Myers Squibb Company; B. Braun SE; Asahi Kasei Medical Co. Ltd.; Nikkiso Co. Ltd.; Abbott Laboratories; Merck Co. & KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. End Stage Renal Disease (ESRD) Drug Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global End Stage Renal Disease (ESRD) Drug Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. End Stage Renal Disease (ESRD) Drug Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global End Stage Renal Disease (ESRD) Drug Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Personalized Esrd Drug Therapy
  • 4.2.2 Home-Based Dialysis Solutions
  • 4.2.3 Telemedicine Integration In Ckd Management
  • 4.2.4 Advanced Drug Formulations For Secondary Complications
  • 4.2.5 Increasing Adoption Of Combination Therapies

5. End Stage Renal Disease (ESRD) Drug Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Homecare
• 5.3 Specialty Clinics
• 5.4 Renal Care Centers
• 5.5 Pharmacies

6. End Stage Renal Disease (ESRD) Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global End Stage Renal Disease (ESRD) Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global End Stage Renal Disease (ESRD) Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global End Stage Renal Disease (ESRD) Drug Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global End Stage Renal Disease (ESRD) Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global End Stage Renal Disease (ESRD) Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global End Stage Renal Disease (ESRD) Drug Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. End Stage Renal Disease (ESRD) Drug Market Segmentation

• 9.1. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
• 9.2. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
• 9.3. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
• 9.4. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.5. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cinacalcet, Etelcalcetide
• 9.6. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Vitamin D, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Calcitriol, Doxercalciferol, Paricalcitol
• 9.7. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Sterols, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ergocalciferol, Cholecalciferol
• 9.8. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Potassium Binders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
• 9.9. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Calcium Acetate, Calcium Carbonate
• 9.10. Global End Stage Renal Disease (ESRD) Drug Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Iron Supplements, Erythropoiesis-Stimulating Agents

10. End Stage Renal Disease (ESRD) Drug Market Regional And Country Analysis

• 10.1. Global End Stage Renal Disease (ESRD) Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global End Stage Renal Disease (ESRD) Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market

• 11.1. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China End Stage Renal Disease (ESRD) Drug Market

• 12.1. China End Stage Renal Disease (ESRD) Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India End Stage Renal Disease (ESRD) Drug Market

• 13.1. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan End Stage Renal Disease (ESRD) Drug Market

• 14.1. Japan End Stage Renal Disease (ESRD) Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia End Stage Renal Disease (ESRD) Drug Market

• 15.1. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia End Stage Renal Disease (ESRD) Drug Market

• 16.1. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea End Stage Renal Disease (ESRD) Drug Market

• 17.1. South Korea End Stage Renal Disease (ESRD) Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan End Stage Renal Disease (ESRD) Drug Market

• 18.1. Taiwan End Stage Renal Disease (ESRD) Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia End Stage Renal Disease (ESRD) Drug Market

• 19.1. South East Asia End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe End Stage Renal Disease (ESRD) Drug Market

• 20.1. Western Europe End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK End Stage Renal Disease (ESRD) Drug Market

• 21.1. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany End Stage Renal Disease (ESRD) Drug Market

• 22.1. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France End Stage Renal Disease (ESRD) Drug Market

• 23.1. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy End Stage Renal Disease (ESRD) Drug Market

• 24.1. Italy End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain End Stage Renal Disease (ESRD) Drug Market

• 25.1. Spain End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe End Stage Renal Disease (ESRD) Drug Market

• 26.1. Eastern Europe End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia End Stage Renal Disease (ESRD) Drug Market

• 27.1. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America End Stage Renal Disease (ESRD) Drug Market

• 28.1. North America End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA End Stage Renal Disease (ESRD) Drug Market

• 29.1. USA End Stage Renal Disease (ESRD) Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada End Stage Renal Disease (ESRD) Drug Market

• 30.1. Canada End Stage Renal Disease (ESRD) Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America End Stage Renal Disease (ESRD) Drug Market

• 31.1. South America End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil End Stage Renal Disease (ESRD) Drug Market

• 32.1. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East End Stage Renal Disease (ESRD) Drug Market

• 33.1. Middle East End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa End Stage Renal Disease (ESRD) Drug Market

• 34.1. Africa End Stage Renal Disease (ESRD) Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. End Stage Renal Disease (ESRD) Drug Market Regulatory and Investment Landscape

36. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape And Company Profiles

• 36.1. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. End Stage Renal Disease (ESRD) Drug Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. End Stage Renal Disease (ESRD) Drug Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. End Stage Renal Disease (ESRD) Drug Market Other Major And Innovative Companies

• Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

38. Global End Stage Renal Disease (ESRD) Drug Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The End Stage Renal Disease (ESRD) Drug Market

40. End Stage Renal Disease (ESRD) Drug Market High Potential Countries, Segments and Strategies

• 40.1 End Stage Renal Disease (ESRD) Drug Market In 2030 - Countries Offering Most New Opportunities
• 40.2 End Stage Renal Disease (ESRD) Drug Market In 2030 - Segments Offering Most New Opportunities
• 40.3 End Stage Renal Disease (ESRD) Drug Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer